Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MIF | P14174 | 2/20 | 0.38 |
| ▸ | HTT | P42858 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.37 |
| ▸ | DAO | P14920 | 3/20 | 0.37 |
| ▸ | MAOA | P21397 | 2/20 | 0.35 |
| ▸ | MAOB | P27338 | 2/20 | 0.35 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.33 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.33 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.33 |
| ▸ | CES2 | O00748 | 1/20 | 0.33 |
| ▸ | CES1 | P23141 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29184207 | 0.85 | DAO (0.42) | MIFALDH1A1DAOACHE | |
| SCHEMBL29170709 | 0.83 | MAPK1 (0.36) | MIF | |
| SCHEMBL854704 | 0.80 | DPP4 (0.40) | MIFDAOMAOAMAOB | |
| SCHEMBL31286093 | 0.80 | AR (0.45) | MIF | |
| SCHEMBL4021438 | 0.80 | KIF11 (0.45) | MIFDAOCYP11B1CYP11B2 | |
| SCHEMBL23686827 | 0.79 | HTT (0.47) | HTTALDH1A1CYP17A1ACHE | |
| SCHEMBL30022093 | 0.79 | HTT (0.47) | HTTALDH1A1CYP17A1ACHE | |
| SCHEMBL855601 | 0.78 | ALDH1A1 (0.53) | HTTALDH1A1 | |
| SCHEMBL855671 | 0.78 | TDP1 (0.50) | ALDH1A1 | |
| SCHEMBL21089 | 0.78 | MIF (0.44) | MIFALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115109019-B | Dehydrocostuslactone derivative, and preparation method and application thereof | 上海医药工业研究院 | 2024-02-02 | — | — | CN | disclosed |
| US-11807646-B2 | 4-hydroxypiperidine derivatives and their use as inhibitors of ubiquitin specific protease 19 (USP19) | ALMAC DISCOVERY LIMITED (GB) | 2023-11-07 | — | — | US | disclosed |
| EP-3746432-B1 | 4-HYDROXYPIPERIDINE DERIVATIVES AND THEIR USE AS INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 19 (USP19) | ALMAC DISCOVERY LTD (GB) | 2022-12-14 | — | — | EP | disclosed |
| CN-115109019-A | Dehydrocostuslactone derivative, preparation method and application thereof | 上海医药工业研究院 | 2022-09-27 | — | — | CN | disclosed |
| CN-114736197-A | Imidazolidinone derivatives and their use | 南京医工医药技术有限公司 | 2022-07-12 | — | — | CN | disclosed |
| US-20220033397-A1 | PHARMACEUTICAL COMPOUNDS AND THEIR USE AS INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 19 (USP19) | ALMAC DISCOVERY LTD (GB) | 2022-02-03 | — | — | US | disclosed |
| EP-3890829-A1 | PHARMACEUTICAL COMPOUNDS AND THEIR USE AS INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 19 (USP19) | Almac Discovery Limited (GB) | 2021-10-13 | — | — | EP | disclosed |
| CN-113365696-A | Pharmaceutical compounds and their use as inhibitors of ubiquitin-specific protease 19(USP19) | 阿尔麦克探索有限公司 | 2021-09-07 | — | — | CN | disclosed |
| US-20210070773-A1 | 4-HYDROXYPIPERIDINE DERIVATIVES AND THEIR USE AS INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 19 (USP19) | ALMAC DISCOVERY LIMITED (GB) | 2021-03-11 | — | — | US | disclosed |
| CN-112135818-A | 4-hydroxypiperidine derivatives and their use as inhibitors of ubiquitin-specific protease 19(USP19) | 阿尔麦克探索有限公司 | 2020-12-25 | — | — | CN | disclosed |
| EP-3746432-A1 | 4-HYDROXYPIPERIDINE DERIVATIVES AND THEIR USE AS INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 19 (USP19) | Almac Discovery Limited (GB) | 2020-12-09 | — | — | EP | disclosed |
| WO-2020115501-A1 | PHARMACEUTICAL COMPOUNDS AND THEIR USE AS INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 19 (USP19) | ALMAC DISCOVERY LIMITED (GB) | 2020-06-11 | — | — | WO | disclosed |
| WO-2019150119-A1 | 4-HYDROXYPIPERIDINE DERIVATIVES AND THEIR USE AS INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 19 (USP19) | ALMAC DISCOVERY LIMITED (GB) | 2019-08-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220033397-A1 | PHARMACEUTICAL COMPOUNDS AND THEIR USE AS INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 19 (USP19) | USP19, USP16, USP18 | MIF 2560/4885HTT 1150/4885ALDH1A1 3271/4885 |
| US-11807646-B2 | 4-hydroxypiperidine derivatives and their use as inhibitors of ubiquitin specific protease 19 (USP19) | USP19, USP16, USP18 | MIF 2413/4885HTT 579/4885ALDH1A1 1427/4885 |
| US-20210070773-A1 | 4-HYDROXYPIPERIDINE DERIVATIVES AND THEIR USE AS INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 19 (USP19) | USP19, USP16, USP18 | MIF 2413/4885HTT 579/4885ALDH1A1 1427/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.